Planatome Appoints Craig Bushnell as Business Development and Chief Commercial Officer to Drive Strategic Growth

Planatome, a leader in low-trauma surgical instruments designed to enhance patient outcomes, today announced the appointment of Craig Bushnell as Business Development and Chief Commercial Officer (CCO). In this role, Bushnell will be responsible for overseeing Planatome’s commercial strategy, business development, and marketing efforts to foster growth and advance the company’s mission delivering low trauma surgical instruments that provide unparalleled healing for patients.

Driving Licensing Expansion and Market Growth

A major focus of Bushnell’s role at Planatome will be to enhance Planatome’s strategic licensing agreements, enabling more healthcare and medical technology partners to integrate Planatome’s surgical technology into their product lines. His vast expertise in business development, commercialization, and market positioning will be crucial in bolstering Planatome’s footprint in the surgical instruments industry.

“Craig’s leadership arrives at a critical juncture as we work to broaden the reach of our technology. His proven success in commercializing medical innovations and forging impactful partnerships will help us accelerate our core purpose of improving the lives of others by delivering low trauma surgical instruments that yield unparalleled healing for patients,” stated Tim Tobin, CEO.

Extensive Experience in Medical Device Leadership

Bushnell is a seasoned medical device executive and commercial leader with 25+ years of experience developing and managing sales and marketing teams in emerging and highly competitive global medical device markets.

During his 18 years at Ethicon Endo-Surgery, Bushnell held various positions of increasing responsibility, including Director of Sales & Marketing at JJKK (Japanese Affiliate) and Director of Market Development, where he played a key role in driving commercial strategy and expanding global market presence.

He later served as Vice President of Sales at Ulthera, Inc., where he was instrumental in building the company from its startup phase through its acquisition. Most recently, he was Vice President of Sales & Marketing at GT Medical Technologies, where he created and led the commercial strategy, team build out, and product launch of GammaTile, a radioactive implant for the treatment of malignant brain tumors.

"I am excited to join Planatome and help accelerate its core purpose of improving lives through breakthrough surgical technology. By applying semiconductor-level precision to medical instruments, we are delivering low-trauma surgical instruments that yield unparalleled healing for patients—especially those disproportionately affected by adverse scarring and chronic wounds. Leveraging my experience, I look forward to collaborating with the team and leading OEMs to expand opportunities, drive innovation, and make a lasting impact on surgical outcomes worldwide."

About Planatome

Planatome is a medical technology company specializing in advanced precision-surface technology that enhances surgical instruments by reducing trauma, improving surgical performance, and optimizing patient recovery. Through strategic licensing agreements, Planatome enables leading medical device manufacturers to integrate its proprietary surface-modification technology into their surgical platforms, setting a new standard in surgical care.

For more information, visit www.Planatome.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219812943/en/